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Abstract 
In-vivo investigation of the volume of the cholinergic basal forebrain and of the 
hippocampus and their relationships to stress-sensitive biomarkers in cerebrospinal fluid (CSF) 
may offer a novel approach for improving our understanding of the pathophysiology of Major 
Depressive Disorder (MDD). Methods: In this study, we investigated the relationship between 
the volume of two brain structures, the Basal Forebrain Cholinergic Nuclei (BFCN) and 
hippocampus and the level of CSF Corticotropin-Releasing Factor (CRF) in older participants 
diagnosed with and without MDD. A standardized clinical evaluation was conducted to assign 
participants into one of two groups (Depressed: n = 28, Healthy controls: n =19), then CSF CRF 
levels and morphologic data were collected. Results: Results showed a positive correlation 
between levels of CRF and BFCN volume in participants with MDD, but not in healthy controls 
where there was a negative trend. Regression analyses showed that after controlling for the main 
effects of diagnosis and CRF, the interaction between CRF and MDD diagnosis was a significant 
predictor of BFCN volume (p = 0.003), but not of hippocampal volume. Conclusions: These 
results suggest that MDD may be characterized by cholinergic system and CRF abnormalities.  
 
Keywords: depression; CSF CRF levels; MRI indices; hippocampus; basal forebrain cholinergic 
system 




 Major depression is a devastating disease that generates significant suffering and cost.  
 After controlling for the main effects of diagnosis and Cerebrospinal Fluid Corticotropin-
Releasing Factor (CSF CRF), the interaction between CSF CRF and major depression 
disorder diagnosis was a significant predictor of basal forebrain cholinergic nuclei 
volume, but not of hippocampal volume. 
 By investigating both markers concurrently in participants with and without depression, 
we describe the extent to which the interaction between CSF CRF levels and depression 
diagnosis is associated with the volume of the forebrain cholinergic nuclei and of the 
hippocampus. 
 These results contribute to our understanding of the role of brain’s stress axis in 
depression. 
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1. Introduction 
Cholinergic innervation of the cerebral cortex, the hippocampus, amygdala, and olfactory 
bulb originates from the basal forebrain area, an area of the brain characterized as a network of 
cholinergic neurons distinguishable by four cell groups (Mesulam et al., 1983a, 1983b). The 
basal forebrain is comprised of (1) the septal area which provides a projection into the 
hippocampus with 10% of its neurons presenting as cholinergic; (2) the diagonal band nucleus, 
comprised of ~70% cholinergic neurons; (3) the horizontal nucleus of the diagonal band, with 
~1% cholinergic neurons, and finally, (4) the nucleus basalis of Meynert, comprised of ~90% 
cholinergic neurons. The basal forebrain is associated with complex behaviors, like wakefulness 
(Anaclet et al., 2015) and learning (Abe et al., 1998; Grothe et al., 2016; Ray et al., 2015) 
depending on widespread cortical innervation originating in the basal forebrain.  
Lines of evidence support the relation between the cholinergic system and depression via 
degeneration of Basal Forebrain Cholinergic Nuclei (BFCN). Pharmacologically, cholinergic 
drugs show an effect on depressive state, as centrally-acting cholinergic medications can induce 
depressive symptoms, while anticholinergic medications can induce antidepressant effects 
(Janowsky et al., 1983). Depressed patients show a hypersensitivity to cholinergic challenge 
(Fritze, 1993), particularly with Rapid Eye Movement induction (Sitaram et al., 1980). 
Cholinergic abnormalities occurs in depression (Mesulam, 2004) and in-vivo molecular imaging 
shows decreased levels of acetylcholinesterase (AChE) in the cerebral cortex, typically 
interpreted as cortical cholinergic denervation due to basal forebrain/nucleus basalis atrophy 
(Bohnen et al., 2007), thereby supporting the hypothesis that depression may be related to 
cholinergic hypofunction. 
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The deficits in basal forebrain signaling may be associated with abnormalities in the 
brain’s stress response system, such that the interaction between glucocorticoids and the 
cholinergic transmitter system contributes to BFCN degeneration (Geerings & Gerritsen, 2017; 
cf, Paul et al., 2015). Corticotropin-releasing factor (CRF), a 41 amino acid peptide, plays a key 
role in mediating adaptive biological and behavioral functions as part of the human stress 
response (Bremner et al., 1997; Ottenweller et al., 1989), and it can be readily measured in the 
Cerebrospinal Fluid (CSF). CRF has also been implicated in the pathophysiology of depression 
(Nemeroff et al., 1984; Owens et al., 1993). Accumulating evidence over the past 30 years 
indicates an association between CRF and MDD. Direct assessment of CRF in human central 
nervous system compartments has been limited to CSF and post-mortem brain examination, but 
CSF levels in MDD has been suggested as a diagnostic and treatment marker for MDD due to 
the significantly increased levels of CRF in depressed patients’ CSF (Kasckow et al., 2001; Keck 
& Holsboer, 2001; Owens et al., 2000) and normalization of CRF levels in conjunction with 
depressive symptom relief (De Bellis et al., 1993; Heuser et al., 1998). Reviews of the literature 
indicate that increased CSF CRF levels have been observed in depressed patients who also 
exhibit a suppressed adrenocorticotropic hormone response to intravenously administered CRF 
(cf, Arborelius et al., 1999). 
The hippocampus is involved in the regulation of stress hormones and with inhibition of 
the adrenocortical stress response (Sapolsky et al., 1984). Hippocampal volume is one of the best 
established structural surrogate measures for HPA axis dysfunction in stress (Sapolsky et al., 
1996). Examining the extent to which basal forebrain and hippocampus volume loss may be 
predicted by depression and by stress exposure may support phenotyping of MDD subtypes that 
are characterized by HPA axis dysfunction and associated cholinergic system abnormalities.  
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The aim of this study was to investigate the association between the effects of depression 
and the level of CSF CRF on hippocampus and BFCN volumes in older participants. This 
offered a unique opportunity to test MRI indices with CRF in an understudied population. To 
investigate the role of the cholinergic hypothesis in depression and associated morphological 
characteristics, we predicted that increased levels of CRF would be associated with decreased 
volumes of both BFCN and the hippocampus in depressed participants, but that there would be 
no observed associations in healthy participants. Second, we predicted that the interaction 
between CSF CRF levels and depression diagnosis would be associated with BFCN and 
hippocampal volume separately.  
 
2. Methods 
2.1. Participants  
Adults living in the US were recruited from the Memory Education and Research 
Initiative (Reichert et al., 2015) as part of a study on late-life MDD (see Pomara et al., 2012 for 
study protocol). This study was approved by the institutional review boards at the Nathan Kline 
Institute for Psychiatric Research and at the New York University Langone Medical Center. One 
hundred and thirty three participants completed the baseline evaluation, 51 completed the 
optional lumbar puncture procedure, three showed evidence in their MRI scans of confluent deep 
or periventricular white matter hyperintensities, defined as one or more hyperintense lesions 
measured at least 10mm in any direction, one had a Mental State Examination (MMSE) score 
below 28, creating a total of 47 participants. The final sample included 28 participants diagnosed 
with MDD and 19 healthy comparison participants. Data on age, education, depression, MMSE, 
and cognitive measures is located in Table 1. The majority of the 28 depressed participants (n = 
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21, 75%) reported a history of depression. Nine participants in the MDD group were likely to be 
in remission, as they endorsed a HAMD score (at screening) of 7 or lower. Sixteen of the 28 
participants were on antidepressants. 
 
2.2. Procedure 
The procedures are described in detail by Pomara et al. (2012). Briefly, cognitively intact 
elderly adults were enrolled into a study consisting of four visits, each approximately one week 
apart. The first visit was used to explain study procedures and obtain informed consent. Data was 
obtained on participants’ medical and psychiatric histories and their vital signs. An assessment of 
the presence or absence of a diagnosis was performed by a board-certified psychiatrist (NP) who 
used the Structured Clinical Interview for DSM-IV Axis I disorders (First et al., 1995). The 
severity of current depressive symptoms was evaluated using the 21-item Hamilton Depression 
Rating Scale (HAM-D), and global cognitive status was evaluated using the MMSE (Folstein et 
al., 1975). A subset of participants offered a collateral source to obtain information regarding the 
presence of dementia (n = 33) using the Clinical Dementia Scale (Morris, 1993). Finally, blood 
was drawn for apolipoprotein E genotyping. During the second visit, participants underwent an 
MRI scan of the head. During the third visit, they underwent a comprehensive 
neuropsychological assessment (Pomara et al., 2012), and in the fourth visit, a lumbar puncture 
on the participants was performed by a neuroradiologist under guided fluoroscopy to obtain a 
CSF sample for analysis.  
 
2.3. Measures 
2.3.1. Structured clinical interview for the DSM-IV Axis I disorders 
BFCN CRF CSF IN MDD   10 
 
Diagnosis was evaluated by a board-certified psychiatrist (NP) using the Structured 
Clinical Interview for the DSM-IV Axis I Disorders (First et al., 1995). This semi-structured 
interview collects information that permits the interviewer to discern the presence of lifetime and 
current psychiatric diagnoses.  
 
2.3.2. Hamilton rating scale for depression  
Depressive symptoms were evaluated using the Hamilton Depression Rating Scale   
(HAM-D, Hamilton, 1967). This is a 21-item clinician-administered scale, which produces a total 
score that reflects the severity of depression. Lower scores (0-7, 8-13) reflect normal range and 
mild depression, respectively. Middling scores (14-19) reflect moderate severity and higher 
scores (20-52) reflect severe to very severe depression. Inter-rater reliability coefficients have 
been reported as > .84 (Schwab, Bialow, Clemmons, & Holzer, 1967). 
 
2.3.3. Clinical dementia rating scale 
A clinician administered the Clinical Dementia Rating Scale (Morris, 1993) to the 
participants, and when available, to their collateral sources. This measure uses a five-point scale 
to assess six domains of cognitive and functional performance applied to dementia. The domains 
include Memory, Orientation, Judgment and Problem-solving, Community Affairs, Home and 
Hobbies, and Personal Care. The participants screened (n = 33) had a score of 0, which reflects 
no cognitive impairment (Morris, 1993). 
 
2.3.4. Mini mental state examination  
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A clinician administered the Mini Mental State Examination (MMSE, Folstein et al., 
1975) to ensure normative cognitive function. The MMSE is an 11-item measure that examines 
five areas of cognitive function: orientation, registration, attention and calculation, recall, and 
language. A lower score represents higher severity of cognitive impairment. Specifically, a score 
of 0-17 suggests severe cognitive impairment, 18-23 suggests mild impairment, and 24-30 
indicates no impairment. 
 
2.3.5. CSF CRF assay 
The CRF levels in the CSF were measured using a CRF ELISA kit (YK132, Human CRF 
ELISA, Yanaihara Institute Inc. Shizuoka, Japan) according to the manufacturer’s instructions. 
Briefly, 50 μl conjugate buffer was added in each well. Then 50 μl of standard (0,0.039, 0.078, 
0.156, 0.313, 0.625, 1.25 and 2.5 ng/ml) or CSF samples ( MDD or controls) were added to the 
wells and incubated at 4°C overnight. After incubation, each well was aspirated and washed with 
wash buffer (200 μl). Next, 100 μl of SA-HRP solution was added into each well and incubated 
for 1 hour at room temperature. The wells were washed 4 times, incubated with 100μl of 
substrate (TMB solution) for 30min at room temperature, and terminated by the stop solution 
(100 μl). The optical density was determined within 10min using a microplate reader (FLUOstar, 
Omego, BMG Labtech) set at 450 nm. All samples were tested in duplicate. The mean 
absorbance values of the standard curve were calculated to determine the value of the samples by 
using the average absorbance reading of each sample. 
 
2.3.6. MRI assessment 
MRI acquisition 
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As per the protocol in Bruno et al., (2015), the MRI acquisition was performed on a 1.5 T 
Siemens Vision system at the Nathan Kline Institute. All images were acquired using a sagittal 
magnetization prepared rapid gradient-echo sequence [IMPRAGE; repetition time (TR)/echo 
time (TE)=11.4/11.9 ms, 1 excitation, (NEX), matrix=256 x 256, FOV=307 mm, 1.2 mm3 
isotropic voxel, 172 slices, no gap]. For evaluation of white matter hyperintensities, we used a 
fluid attenuated inversion recover sequence [FLAIR: TR/TE=9000/199 ms, inversion time = 
2400 ms, NEXT=1, matrix 256 x 256, FOV=240 mm, slice thickness= 4 mm, 1 mm gap]. 
 
MRI preprocessing and analysis 
Briefly, MPRAGE images were segmented into gray matter, white matter, and 
cerebrospinal fluid, and high-dimensionally registered to Montreal Neurological Institute (MNI) 
standard space, using a fully automated segmentation routine and the DARTEL algorithm for 
diffeomorphic nonlinear inter-subject registration, both available in the VBM8 toolbox. Warping 
parameters were applied to individual gray matter maps and voxel values were modulated to 
account for the volumetric differences introduced by the high-dimensional warps. 
 Individual volumes of the hippocampus and the BFCN were extracted automatically from 
the warped grey matter segments by summing up the modulated voxel values within respective 
regions-of-interest masks in template space. The hippocampus mask was obtained by direct 
manual delineation of the hippocampus in the MNI standard space template following a recently 
developed international consensus protocol for manual hippocampus segmentation on MRI 
(Frisoni et al., 2015; http:// www.hippocampal-protocol.net/SOPs/index.php). The BFCN mask 
was based on an MNI standard space stereotactic map of cholinergic nuclei in the basal 
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forebrain. This map was created using combined post-mortem MRI and histologic delineation of 
the BFCN in an autopsy brain, as described in detail previously (Kilimann et al., 2014). The 
Total Intracranial Volume (TIV) was used in the statistical model to account for differences in 
head size, and was calculated as the sum of the total segmented gray matter, white matter, and 
cerebrospinal fluid volumes in native space. 
 
2.4. Statistical analyses 
Demographic and clinical characteristics were summarized. An ANCOVA, controlling 
for TIV, was conducted to compare absolute volume of hippocampus and of BFCN. Two partial 
correlations were conducted to evaluate the strength and direction of the relationship between 
CSF CRF levels and BFCN volume, one in the depressed and one in the control group, 
controlling for TIV and age in both. Then, two additional correlations were conducted to test the 
strength and direction of the relationship between CSF CRF levels and hippocampal volume in 
the depressed and healthy group, controlling for TIV and age in each. Then, we correlated 
depression severity in the depressed sample with hippocampal volume and with BFCN, 
controlling for TIV. Following these tests, we conducted two forced-entry multiple regression 
analyses, replacing missing values with average scores. Using the total sample, the first 
regression aimed to test the extent to which the interaction between CSF CRF levels and 
depression diagnosis predicted the volume of BFCN, controlling for the influence of TIV, CRF, 
and age. The second regression aimed to test the extent to which the interaction between CSF 
CRF levels and depression diagnosis predicted the volume of the hippocampus, again, 
controlling for the influence of TIV, CRF, and age. We used BFCN and hippocampal volume 
data from the MR images as the dependent variables and Z scores for CRF, TIV, age and 
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diagnosis as the independent variables. Preliminary analyses were performed to ensure that there 
was no violation of the assumption of normality, linearity, multicollinearity, and 
homoscedasticity.  
All tests were two-tailed, and statistical significance was established at an alpha of 0.05. 




The sample was primarily male (n = 25, 56.8%, females n = 22), in their mid-to late sixties 
(M = 67.3 years, SD = 6.35y), and college educated (M = 16.6, SD = 2.7). The sample was 
cognitively intact per the MMSE (M = 29.7, SD = 0.6). Participants in the depressed group were 
either currently depressed or partially remitted, 21 participants reported recurrent depression, and 
15 were taking antidepressants. A comparison of the depressed (n = 28) group vs. the healthy 
comparison group (n = 19) showed a significant difference on depressive severity per the HAM-
D (t(1,45) = 8.02, p < 0.001). Specifically, the depressed group had a significantly higher 
severity of current depressive symptoms (M = 14.9, SD = 8.8) relative to healthy controls (M = 
1.2, SD = 1.9). No group differences were observed by age (t(1,45) = 0.835, p = 0.41), number of 
women (χ2(1, 45) = 2.4, p = 0.12), and years of education (t(1,44) = 0.274, p = 0.79). 
Demographic and clinical information by group is described in Table 1 and in Pomara et al., 
(2012).  
 
3.2. Analyses of Covariance and tests of association 
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Analyses of covariance revealed no differences of the absolute values of BFCN volume 
by group, controlling for TIV, F(1,44)=2.508, p=0.120, Healthy = 548.67 (SD = 68.48); MDD = 
585.77 (SD = 79.10). Similarly, no group difference emerged with hippocampal volume, 
F(1,44)=0.032, p=0.859, Healthy = 7036.24 (SD = 836.00); MDD = 7071.43 (SD = 550.91). 
Absolute values of TIV by group are similar (Healthy = 1346.54 (SD = 164.64); MDD = 1366.28 
(SD = 139.19). 
Within the depressed group, a positive correlation was observed between CSF CRF and 
BFCN volume, when controlling for TIV and age, r = 0.481, p = 0.013, R2= 0.231. Among 
healthy controls, in contrast, no analogous significant correlation was found, r = -0.295, p = 
0.250, R2 = 0.063.  
Within the depressed group, no significant correlation was observed between CRF and 
hippocampal volume, when controlling for TIV and age, r = 0.320, p = 0.111, R2= 0.102. Among 
healthy controls, no significant correlation was found, r = -0.096, p = 0.715, R2 = 0.009.  
Depression severity (HAMD) at the screening assessment in the depressed sample did not 
correlate with either hippocampal volume (r = 0.251, p = 0.206) or BFCN (r = 0.077, p = 0.702) 
when controlling for TIV. Figure 1 provides a scatterplot of the distribution of associations.  
 
INSERT FIGURE 1 HERE 
 
3.3. Regression models 
In the first regression, age, sex, MDD status, TIV, and CRF were entered in Step 1. 
Results explained 27.2% of the variance in BFCN volume, F(5, 41) = 3.069, p = 0.019. The 
interaction term (CRF × MDD) was entered in Step 2, significantly increasing the total variance 
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explained by the model to 42.2%, F(1, 40) = 10.313, p = 0.003, thereby explaining an additional 
15% of the variance in BFCN volume. These results reflect a positive interaction between CRF 
and MDD, which can be interpreted to mean that more CRF in MDD reflects higher BF volume. 
In the second regression, age, sex, MDD status, TIV, and CRF were entered in Step 1. 
Results explained 59.9% of the variance in hippocampal volume, F(5, 41) = 10.413, p< 0.001. 
The interaction term (CRF × MDD) was entered in Step 2 and did not significantly increase the 
total variance explained, F(1, 40) = 2.69, p = 0.109, adding only 3% to the variance explained in 
hippocampal volume. The highest VIF score was 1.118, which is low and would suggest that 
multicollinearity did not play a role. Tables 1 and 2 outline the results.  
 
INSERT TABLES 1 TO 3 HERE 
 
4. Discussion 
Our results showed a positive association between CRF and BFCN volume among 
depressed participants, but not among healthy controls. This was confirmed by both partial 
correlations and the significant interaction between CSF CRF levels and MDD diagnosis and 
BFCN volume. These results suggest there may be a cholinergic associated increase in brain 
CRF that may potentially contribute to the association between increased cholinergic tone and 
depression. Larger BFCN volumes may be interpreted as reflecting an increase of cholinergic 
activity. Though the smaller volumes, suggesting hypofunction, is a common interpretation of 
volumetric studies, the bigger volumes, suggesting hyperactivity, is not as widely accepted. In a 
study by Butler et al. (2013), basal forebrain septal nuclei volumes were found to be bigger in 
participants with temporal lobe epilepsy, which was also interpreted to be reflective of 
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dysfunctional hyperactivity. Animal studies also suggest that septal cholinergic neurons are 
resistant to seizure-related neuronal loss, and that nerve growth factor released from the 
hippocampus and transferred to septal nuclei may increase the number of cholinergic neurons, 
thereby increasing regional volume. 
After the covariates were entered, which accounted for more than 40% of the variance, 
the level of CRF by depression status explained an additional 15% of the variance in BFCN 
volume. The participants’ age was controlled for as prior research shows that decreasing size of 
cholinergic neurons in the basal forebrain are correlated with increasing age (Mesulam, Mufson, 
Rogers, 1987). In contrast, the combination of the covariates in the hippocampal regression 
predicted almost 60% of the hippocampal volume, to which the CRF × MDD interaction term 
contributed a very modest three percent, offering limited information in the prediction of 
hippocampal volume. Hippocampal volume changes in MDD have provided conflicting results 
though most studies have reported smaller volumes in MDD with increased neuronal loss in 
patients and preclinical models (Booij, 2015; Gerritsen et al., 2011; Wisse, 2015). One study that 
included 636 participants (81% male) found decreased hippocampal volume in MDD (Gerritsen 
et al., 2011), however this decrease was not explained by HPA axis activity. Other studies 
demonstrated smaller hippocampal volumes in samples comprised of mostly or all women 
(Booij, 2015, Elbejjani, 2015). The sample size of the current study may not have been sufficient 
to detect a loss of hippocampal volume, and it would be of interest to conduct a larger study with 
men and women to test for main effects.  
CSF CRF is hypothesized to originate from hypothalamic neurons and/or extra-
hypothalamic CRF-neurons in the BFCN; however the anatomical origin of CRF effects in MDD 
has not been identified. Preclinical studies may help to identify brain regions that contribute to 
BFCN CRF CSF IN MDD   18 
 
CSF CRF levels. The observed elevation in CSF CRF associated with depression has been 
shown to be state-dependent (Banki et al., 1987; Geracioti et al., 1997; Heuser et al., 1998; 
Nemeroff et al., 1984; Nemeroff et al., 1991). In these studies, antidepressants (which reduce 
CSF CRF) were discontinued prior to lumbar puncture. In our study, patients who were taking 
antidepressants were allowed to continue on these medications. Also, the CSF elevations may be 
prominent in melancholic depression (De Jong & Roy, 1990) of which only a few of our patients 
met this criterion. In De Jong et al., (1990) CSF CRF did not correlate with depressive severity, 
but only with certain items. Future research may address the possibility that cognitive and 
affective dimensions are related to CSF CRF.  
To the extent that these results can be replicated, our results would be consistent with the 
research that links increased cholinergic tone to MDD. For example, Williams et al. (2013) 
collected 41 coronal blocks within the nucleus basalis of individuals, aged 41-60 years, 
diagnosed with either major depressive disorder (n=11, of which 7 died of suicide or 
asphyxiation), schizophrenia (n=13) or with age-matched controls (n=16). Examining cell 
density and neuroarchitecture, results indicated a larger nucleus basalis oval neuron soma in the 
combined clinical groups (p = 0.038), with no significant differences between controls and 
schizophrenia and major depression disorder separately. In depression, there was a trend towards 
reduced oligiodendrocyte density (p = 0.065) in nucleus basalis. Notably, the ratio of 
gemistocytic to fibrillary astrocytes was highest among depressed participants (39.9%) relative to 
schizophrenia (18.1 %) and controls (7.9 %). These results suggest glial cell abnormalities in the 
nucleus basalis among depressed individuals, which may be reflected in increased volumes of 
this region, and if replicated, may be useful in further characterizing the neuropathology of 
depression.  
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 To the extent that the anticholinergic effects of antidepressant treatment and other 
medications influenced cholinergic basal forebrain volume, they might have contributed to the 
positive correlation between CRF levels and BFCN volume. We are unable to fully test the 
influence of medications as the small sample size constrains the opportunity to statistically 
control for MDD participants who might have been taking medications with central 
anticholinergic effects. However, we found that cerebrospinal anticholinergic activity (CSF AA) 
determined using a radioreceptor method (Mulsant et al. 2003; Tune & Coyle, 1980) originally 
developed for serum, but successfully also employed for determining CSF AA (Watne et al. 
2014) showed no difference between the MDD and controls. Also, CSF AA showed no 
correlation with BFCN and with hippocampal volume. Therefore, it is unlikely that this factor 
contributed to our results. 
The following limitations of the study should be observed. First, the sample size was 
lower than preferred, given the combination of the covariates in the regression. Second, there 
was heterogeneity of the clinical severity with some participants reporting that they were highly 
likely or very likely to be remitted. Third, the study design was cross-sectional, which constrains 
our ability to test the specificity of the cholinergic hypothesis of depression. Fourth, though 
education is correlated with hippocampal volume (Janowitz et al. 2014) and may need to be 
statistically controlled (Brown et al., 2012) we did not conduct this in our sample as we found no 
group difference in educational levels. Fifth, the results may apply only to late-life onset 
depression given the sample characteristics, thus these results may not apply to individuals under 
age 50y. Finally, the use of antidepressants has the potential to influence hippocampal volume in 
participants with depression (cf. Malykhin & Coupland, 2015), and thus consideration of the 
effects of medication should be considered in terms of effect on hippocampal volume.  
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Further investigation is needed to test the cholinergic hypothesis of depression, beginning 
with an investigation of the specific nature of the two-way interaction of depression and CRF to 
more usefully describe the deeper phenotype of depression, with an unmedicated sample across 
the lifespan. Finally, future work may benefit from a closer evaluation of the clinical 
characteristics and their relation to the BFCN to identify the pathophysiology of MDD. Also, it 
should be noted that in BFCN, besides the cholinergic neurons, GABAergic and glutamatergic 
neurons also constitute this structure (Chen et al., 2016; Hassani et al., 2009). The possible role 
of GABAergic and glutamatergic neurons within the BFCN as possible mediators of its 
relationship to CRF in MDD needs to be determined. Determining the relationship between CRF 
levels with ACh, GABA and glutamate in CSF may help to clarify the underlying mechanisms of 
the cholinergic regulation in BFCN associated with CRF in MDD.  
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Table 1. Demographic and Memory Characteristics of Study Participants 





Comparison Group MDD Group  
 (N=19) (N=28)  p values (t tests) 
Age (years) 68.1 ± 7.3 66.5 ± 5.4 0.41 
Education (years)a 16.7 ± 2.7 16.5 ± 2.7 0.79 
21-item HAM-D 1.2 ± 1.9 14.9 ± 8.8 <0.001 
MMSE 29.5 ± 0.5 29.8 ± 0.6 0.13 
Total recall rating 64.4 ± 12.3 64.9 ± 13.9 0.91 
Delayed recall rating 8.5 ± 2.8 9.5 ± 2.5 0.22 
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Table 2 














      
Sex 0.316 1.978 0.055 0.206 0.298 
CRF 0.130 1.046 0.302 0.218 0.163 
TIV 0.013 0.089 0.930 0.209 0.014 
Age -0.337 -2.528 0.016* -0.338 -0.371 
MDD Status -0.154 -1.219 0.230 -0.241 -0.189 
CRF × MDD -0.405 -3.211 0.003* -0.431 -0.453 
 
Legend. CRF = Corticotropin-Releasing Factor, TIV = Total Intracranial Volume, MDD Status = 
Major Depressive Disorder. 
1 = coded as control, 0 = MDD-status or equivalent. 
*p < 0.05   **p < 0.01  
 
  
BFCN CRF CSF IN MDD   32 
 
Table 3 














      
Sex 0.221 1.638 0.109 -0.208 0.166 
CRF 0.031 0.295 0.770 0.135 0.030 
TIV 0.575 4.619 0.000 0.675 0.469 
Age -0.305 -2.714 0.100 -0.208 -0.276 
MDD Status  0.073   0.686 0.497 -0.026 -0.070 
CRF × MDD -0.174 -1.639 0.109 -0.271 -0.166 
 
Legend. CRF = Corticotropin-Releasing Factor, TIV = Total Intracranial Volume,  
MDD Status = Major Depressive Disorder. 
1 = coded as control, 0 = MDD-status or equivalent. 
*p < 0.05   ** p < 0.01 
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Figure 1 
Distribution of the Association of MRI Index and CRF of Hippocampal Volume (A) and Basal 















































Legend. CRF = Corticotropin-Releasing Factor. MRI Index = Magnetic Resonance Imaging 
Index; Black/full line = depressed subjects; Gray/dashed line = control depressed subjects.  
